Natural killer cell therapy:the key to tackle the bottleneck of cell therapies against solid tumor?  

NK细胞治疗:突破实体瘤细胞治疗瓶颈的关键?

作　　者：Dawei Wu Huilei Miao Xiaoxue Ma Matthew Paul McCormack Huiyao Huang Xiaodong Liu Ning Li 吴大维;苗会蕾;马小雪;Matthew Paul McCormack;黄慧瑶;刘晓东;李宁

机构地区：[1]Clinical Trials Center,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]School of Life Sciences,Westlake University,Hangzhou 310030,China [3]Research Center for Industries of the Future,Westlake University,Hangzhou 310030,China [4]Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou 310030,China [5]Westlake Institute for Advanced Study,Hangzhou 310030,China [6]iCamuno Biotherapeutics,Pty Ltd,Melbourne,3004,Australia [7]Australian Centre for Blood Diseases,Monash University,Melbourne,3004,Australia

出　　处：《Science Bulletin》2025年第5期630-633,共4页科学通报(英文版)

基　　金：Chinese Academy of Medical Sciences Medical and Health Science and Technology Innovation Project(2023-I2M-C&T-B-094);Beijing Nova Program(20230484277);National key research and development program(2023YFC2508500).

摘　　要：Chimeric Antigen Receptor(CAR)T-cell therapy has shown significant success in hematological cancers,leading to the approval of several products and underscoring the potential of immunotherapy in cancer treatment.However,its effectiveness in treating solid tumors remains suboptimal[1].Nearly twenty years ago,natural killer(NK)cell therapy emerged as a potential treatment for leukemia.Since then,NK cells have demonstrated promising antitumor activity in preclinical and clinical studies.Their notable advantages,such as a stronger safety profile and broader availability,make them particularly appealing for solid tumor treatment.Currently,NK cell therapy is a highly active area of research,with over 100 clinical studies underway,covering NK cells from various sources,both engineered and non-engineered,as well as their use in combination therapies with other agents.Here,we highlight its advantages over T cell therapy in the treatment of solid tumors,and summarize the current challenges,potential solutions,and future directions of NK cell therapy development.

关 键 词：KILLER SOLID APPROVAL 

分 类 号：R73[医药卫生—肿瘤]